Aluminum Phosphide PoisoningNCT05215444
Evaluation of Some Prognostic Factors in Acute Aluminum Phosphide Intoxicated Cases
An observational study of Aluminum Phosphide Poisoning, run by Zagazig University at 1 site in Egypt.
Trial summary
study of some laboratory and clinical findings which may show the severity of aluminium phosphide toxicity and the need of the cases to be admitted to ICU Read more about this study
- Who is it for?
- Ages 15 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Aluminum Phosphide Poisoning
- What is being tested?
- some prognostic factors
- How many people
- 42 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2021to 30 Jun 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 45 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: the mode of toxicity is suicidal by ingestion of AlP tablet
Who may be able to join
- History of exposure or intake of Aluminum phosphide.
- Clinical picture of Acute Aluminum phosphide poisoning including severe vomiting, hypotension, abdominal pain, cardio-pulmonary distress.
- Cases of the age of 15 to 45 years old
Who cannot join
- 1. Cases with an unclear history. 2. History of co-morbidities or systemic diseases because of the possibility of misleading laboratory results.
- 3. History of co-ingestion of drugs or another poison.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Faculty of Medicine Zagazig University
Zagazig, Sharqia Province, 44511
About this study
study of some laboratory and clinical findings which may show the severity of aluminium phosphide toxicity and the need of the cases to be admitted to ICU
Read the detailed description
aluminium phosphide poisoning is a major cause of death in intoxicated and suicidal cases since there is no antidote and there is no specific investigation for it so there is a need for further study to identify the cause of death and the most specific investigation in the case of AlP toxicity
- Conditions
- Aluminum Phosphide Poisoning
- Being tested
- some prognostic factors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
some prognostic factorsDiagnostic test
cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count
| Study group | Role | What they receive |
|---|---|---|
| survivors | Not described Receives: Diagnostic Test: some prognostic factors | |
| non survivors | Not described Receives: Diagnostic Test: some prognostic factors |
What is being measured
The primary outcome is the main question the study is designed to answer.
prognosis
predict the mortality of intoxicated AlP cases
Measured: the first 24 post poisoning
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2022
- Study start1 Jan 2021
- Primary completion30 Jan 2021
- Study completion30 Jun 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aluminum Phosphide PoisoningStudies of the same condition, open and under way.
- More trials run by Zagazig UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zagazig University
- Sponsor type
- Other government
- Responsible party
- Principal investigator, shymaa mohamed nasrallah abdulrhman, Zagazig University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05215444
- Sponsor's protocol ID
- 6665
- Status last verified
- Jan 2023
- First submitted
- 17 Jan 2022
- Last updated
- 26 Jan 2023
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Some Prognostic Factors in Acute Aluminum Phosphide Intoxicated Cases
- ClinicalTrials.gov ID
- NCT05215444
- Acronym / sponsor ID
- 6665
- Conditions
- Aluminum Phosphide Poisoning
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Zagazig UniversityOther government
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 30 Jan 2021 (actual)
- Study completion
- 30 Jun 2021 (actual)
- First posted
- 31 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
study of some laboratory and clinical findings which may show the severity of aluminium phosphide toxicity and the need of the cases to be admitted to ICU
Detailed description
aluminium phosphide poisoning is a major cause of death in intoxicated and suicidal cases since there is no antidote and there is no specific investigation for it so there is a need for further study to identify the cause of death and the most specific investigation in the case of AlP toxicity
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| survivors | – | Diagnostic Test: some prognostic factors |
| non survivors | – | Diagnostic Test: some prognostic factors |
Who may qualify
- Ages
- 15 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- the mode of toxicity is suicidal by ingestion of AlP tablet
Key inclusion criteria (3 listed)
- History of exposure or intake of Aluminum phosphide.
- Clinical picture of Acute Aluminum phosphide poisoning including severe vomiting, hypotension, abdominal pain, cardio-pulmonary distress.
- Cases of the age of 15 to 45 years old
Key exclusion criteria (2 listed)
- 1. Cases with an unclear history. 2. History of co-morbidities or systemic diseases because of the possibility of misleading laboratory results.
- 3. History of co-ingestion of drugs or another poison.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| some prognostic factorscortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count | Diagnostic test | non survivors, survivors |
Primary outcome
prognosis
Time frame: the first 24 post poisoning
predict the mortality of intoxicated AlP cases
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2023.
- Individual participant dataSharing planned: No
Related trials for Aluminum Phosphide Poisoning
RecruitingPhase 3
Assessment of The Potential Therapeutic Effects of Trimetazidine on Aluminium Phosphide-Induced Cardiotoxicity as an Adjuvant Therapy: A Pilot Study
Aluminum Phosphide Poisoning
Recruiting
Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning
Toxicity, Drug
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aluminum Phosphide Poisoning, run by Zagazig University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
prognosis (time frame: the first 24 post poisoning). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2023.